AC-93253 triggers the downregulation of melanoma progression markers and the inhibition of melanoma cell proliferation
AC-93253 triggers the downregulation of melanoma progression markers and the inhibition of melanoma cell proliferation
复制标题
DOI：
10.1016/j.cbi.2015.04.016
复制
发表时间：
2015-07-05
影响因子：
5.1
通讯作者：
Ratajewski, Marcin
中科院分区：
文献类型：
--
作者：
Karwaciak, Iwona;Gorzkiewicz, Michal;Ratajewski, Marcin
A major challenge in anti-melanoma therapy is to develop treatments that are effective for advanced melanoma patients. Unfortunately, the currently used regimens are not efficient and have unsatisfactory effects on disease progression, thus increasing the pressure to develop new, profitable drugs and to identify new molecular targets. Here, we show for the first time that AC-93253, a SIRT2 inhibitor, exerts a negative effect on the expression of a set of genes involved in the progression and chemoresistance (e.g., oncogenes, apoptosis-related genes, ABC transporter genes, and cell cycle control genes) of melanoma cells. Furthermore, melanoma cells exposed to AC-93253 and doxorubicin displayed altered biological responses, including apoptosis and proliferation, compared to cells exposed to single treatments. Taken together, we conclude that the usage of AC-93253 in combined therapy could be a promising strategy for melanoma patients. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
